Leukemia

An expert and a patient discuss their experiences with Tecartus, the newly approved CAR-T cell therapy for certain patients with acute lymphoblastic leukemia.

Natural killer cell therapy is making strides in blood cancer research, but there’s still much more to learn.

After undergoing treatment for leukemia in the middle of his career as a radiation oncologist, Dr. Curtis Mack noticed that he became a more empathetic and patient doctor.

Dr. Curtis Mack can relate to his patients on a level other radiation oncologists might not be able to because he has received a diagnosis, gone through treatment and survived cancer himself.

An expert discusses two primary unmet needs in myelofibrosis, current treatments and new approaches to this complex disease.

The FDA approved Tecartus, a CAR-T cell therapy, for the treatment of patients with relapsed/refractory acute lymphoblastic leukemia.

While the recent FDA approval of Jakafi offers another effective option for patients with chronic GVHD, one expert urges that more work needs to be done to prevent and/or reverse the condition.

The FDA has granted approval to Jakafi (ruxolitinib) for the treatment of chronic graft-versus-host disease (GVHD).

Patients with blood cancer who underwent stem cell transplant and developed chronic graft-versus-host disease have more treatment options than ever before. But the formula for planning older and newer therapies has not yet been established.

The use of convalescent plasma therapy in patients with blood cancers and COVID-19 was associated with an improvement in survival from the infection.

Mel Mann, the longest living person who participated in the clinical trial for Gleevec – which was approved by the FDA just over 20 years ago – shares what he would tell his younger self.

Adolescent and young adult patients are more represented than previously expected in clinical trials. However, their outcomes still lag behind the younger and older populations.

Treatment for acute lymphoblastic leukemia can be long and difficult at times, but the end goal is curing the disease.

View the full CURE Educated Patient Leukemia Summit on demand.

The FDA approval of Rylaze provides certain patients with leukemia and lymphoma with an on-demand treatment option since the only other approved therapy is currently undergoing a shortage.

The FDA approval provides patients with an alternative therapy to the only other approved treatment, which has been under a global shortage for several years.

Although recent data show how promising a single-infusion of a specific CAR-T cell therapy may be for patients with acute lymphoblastic leukemia, an expert from the Moffitt Cancer Center notes that more research is needed for those deemed too ill to receive the treatment.

Patients with relapsed/refractory acute lymphoblastic leukemia may have prolonged survival with Blincyto, especially among those who undergo hematopoietic stem cell transplantation.

From the first COVID-19 vaccine doses becoming available for patients and their caregivers at a cancer center in Texas to community police officers delivering food to families impacted by cancer in Philadelphia, here’s what’s happening in the cancer landscape this week.

Over the past decade, advances in both diagnostics and therapeutics in a variety of blood cancers have turned certain diseases into chronic conditions.

Patients with chronic myeloid leukemia are living longer, some even stopping treatment, thanks to a plethora of targeted therapies.

Oncologists and researchers are racing to identify new therapies to help better treat a rare form of acute lymphoblastic leukemia.

Blood shortages during the COVID-19 pandemic have forced cancer centers to get creative to ensure patients with hematologic malignancies are able to get transfusions in a timely manner.

The Food and Drug Administration has granted the investigational therapy asciminib a breakthrough therapy designation for the treatment of certain adults with Philadelphia chromosome-positive chronic myeloid leukemia. The designation may allow for expedited review of the drug.